Patents by Inventor Libing Chen

Libing Chen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Secondary battery and apparatus containing the secondary battery
    Patent number: 12230800
    Abstract: This application discloses a secondary battery including a positive electrode plate and a negative electrode plate, wherein the positive electrode plate comprises a positive electrode current collector and a positive electrode film disposed on a surface of the positive electrode current collector and comprising a positive active material, the negative electrode plate comprises a negative electrode current collector and a negative electrode film disposed on a surface of the negative electrode current collector and comprising a negative active material. The positive active material comprises one or more of layered lithium transition metal oxides and modified compounds thereof, and a resistance R of the negative electrode plate satisfies: 6.0 m??R?12.0 m?; or the positive active material comprises one or more of lithium-containing phosphates with olivine structure and modified compounds thereof, and a resistance R of the negative electrode plate satisfies: 3.0 m??R?7.0 m?.
    Type: Grant
    Filed: December 10, 2021
    Date of Patent: February 18, 2025
    Assignee: CONTEMPORARY AMPEREX TECHNOLOGY (HONG KONG) LIMITED
    Inventors: Jianjun Ma, Rui Shen, Libing He, Baojian Zhu, Lei Chen
  • Cyclic dinucleotides as anticancer agents
    Patent number: 11427610
    Abstract: The present invention is directed to compounds of the formula wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
    Type: Grant
    Filed: October 16, 2018
    Date of Patent: August 30, 2022
    Assignee: Bristol-Myers Squibb Company
    Inventors: Brian E. Fink, Yufen Zhao, Libing Chen, Audris Huang
  • Cyclic dinucleotides as anticancer agents
    Patent number: 11339185
    Abstract: The present invention is directed to compounds of the formulae I, II and III as shown below wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
    Type: Grant
    Filed: November 14, 2019
    Date of Patent: May 24, 2022
    Assignee: Bristol-Myers Squibb Company
    Inventors: Brian E. Fink, Dharmpal S. Dodd, Steven J. Walker, Libing Chen, Yufen Zhao, Zheming Ruan, Lan-Ying Qin, Peter Kinam Park, Muthoni G. Kamau, Lalgudi S. Harikrishnan
  • CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS
    Publication number: 20210253624
    Abstract: The present invention is directed to compounds of the formula wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
    Type: Application
    Filed: October 16, 2018
    Publication date: August 19, 2021
    Inventors: Brian E. FINK, Yufen Zhao, Libing Chen, Audris Huang
  • Cyclic dinucleotides as anticancer agents
    Patent number: 10947263
    Abstract: The present invention is directed to compounds of the formula (I) wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
    Type: Grant
    Filed: August 30, 2018
    Date of Patent: March 16, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: Lan-Ying Qin, Zheming Ruan, Libing Chen, Scott Hunter Watterson, Brian E. Fink
  • CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS
    Publication number: 20200223883
    Abstract: The present invention is directed to compounds of the formula (I) wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
    Type: Application
    Filed: August 30, 2018
    Publication date: July 16, 2020
    Inventors: Lan-Ying Qin, Zheming Ruan, Libing Chen, Scott Hunter Watterson, Brian E. Fink
  • CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS
    Publication number: 20200079815
    Abstract: The present invention is directed to compounds of the formulae I, II and III as shown below wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
    Type: Application
    Filed: November 14, 2019
    Publication date: March 12, 2020
    Inventors: Brian E. FINK, Dharmpal S. Dodd, Steven J. Walker, Libing Chen, Yufen Zhao, Zheming Ruan, Lan-Ying Qin, Peter Kinam Park, Muthoni G, Kamau, Lalgudi S. Harikrishnan
  • Cyclic dinucleotides as anticancer agents
    Patent number: 10519187
    Abstract: The present invention is directed to compounds of the formulae I, II and III as shown below wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
    Type: Grant
    Filed: February 11, 2019
    Date of Patent: December 31, 2019
    Assignee: Bristol-Myers Squibb Company
    Inventors: Brian E. Fink, Dharmpal S. Dodd, Steven J. Walker, Libing Chen, Yufen Zhao, Zheming Ruan, Lan-Ying Qin, Peter Kinam Park, Muthoni G. Kamau, Lalgudi S. Harikrishnan
  • CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS
    Publication number: 20190248828
    Abstract: The present invention is directed to compounds of the formulae I, II and III as shown below wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
    Type: Application
    Filed: February 11, 2019
    Publication date: August 15, 2019
    Inventors: Brian E. Fink, Dharmpal S. Dodd, Steven J. Walker, Libing Chen, Yufen Zhao, Zheming Ruan, Lan-Ying Qin, Peter Kinam Park, Muthoni G. Kamau, Lalgudi S. Harikrishnan
  • IDO inhibitors
    Patent number: 9758492
    Abstract: There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or autoimmune diseases utilizing the compounds of the invention.
    Type: Grant
    Filed: August 26, 2014
    Date of Patent: September 12, 2017
    Assignees: Bristol-Myers Squibb Company, Syngene International Limited, Syngene International Limited
    Inventors: Jay A. Markwalder, Steven P. Seitz, James Aaron Balog, Audris Huang, Sunil Kumar Mandal, Shefali Srivastava, David K. Williams, Libing Chen
  • Inhibitors of indoleamine 2,3-dioxygenase (IDO)
    Patent number: 9675571
    Abstract: There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: June 13, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: James Aaron Balog, Audris Huang, Bin Chen, Libing Chen, Steven P. Seitz, Amy C. Hart, Jay A. Markwalder
  • IDO inhibitors
    Patent number: 9624188
    Abstract: There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or autoimmune diseases utilizing the compounds of the invention. Formula (I).
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: April 18, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: James Aaron Balog, Audris Huang, Bin Chen, Libing Chen, Weifang Shan
  • Fluoroalkyl and fluorocycloalkyl 1,4-benzodiazepinone compounds
    Patent number: 9427442
    Abstract: Disclosed are compounds of Formula (I): (Formula (I)) wherein: R1 is —CH2CH2CF3; R2 is —CH2CH2CH2F, —CH2CF2CH3, —CH2CH2CF3, —CH2CH(CH3)CF3, —CH2CH2CF2CH3, (Formulae (II), (III), (IV), (V) or (VI): R3 is H or —CH3; Ring A is phenyl or pyridinyl; and Rx, Ry, Ra, Rb, y, and z are defined herein. Also disclosed are methods of using such compounds to inhibit the Notch receptor, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as cancer.
    Type: Grant
    Filed: September 20, 2013
    Date of Patent: August 30, 2016
    Assignee: Bristol-Myers Squibb Company
    Inventors: Yufen Zhao, Ashvinikumar V. Gavai, Patrice Gill, Soong-Hoon Kim, Brian E. Fink, Libing Chen, Mark G. Saulnier, Wen-Ching Han
  • IDO INHIBITORS
    Publication number: 20160200674
    Abstract: There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or autoimmune diseases utilizing the compounds of the invention.
    Type: Application
    Filed: August 26, 2014
    Publication date: July 14, 2016
    Applicant: Bristol-Myers Squibb Company
    Inventors: Jay A. Markwalder, Steven P. Seitz, James Aaron Balog, Audris Huang, Sunil Kumar Mandal, Shefali Srivastava, David K. Williams, Libing Chen
  • Imidazopyridazinecarbonitriles useful as kinase inhibitors
    Patent number: 9371328
    Abstract: The invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. The Formula (I) imidazopyridazines inhibit protein kinase activity thereby making them useful as anticancer agents.
    Type: Grant
    Filed: February 27, 2014
    Date of Patent: June 21, 2016
    Assignee: Bristol-Myers Squibb Company
    Inventors: Brian E. Fink, Libing Chen, Ashvinikumar V. Gavai, Liqi He, Soong-Hoon Kim, Andrew James Nation, Yufen Zhao, Litai H. Zhang
  • IMIDAZOTRIAZINECARBONITRILES USEFUL AS KINASE INHIBITORS
    Publication number: 20160108050
    Abstract: The invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. The Formula (I) imidazotriazines inhibit protein kinase activity thereby making them useful as anticancer agents.
    Type: Application
    Filed: December 21, 2015
    Publication date: April 21, 2016
    Inventors: Ashok Vinayak Purandare, Brian E. Fink, Walter Lewis Johnson, Amy C. Hart, Liqi He, Tram N. Huynh, Jennifer lnghrim, Harold Mastalerz, Xiaopeng Sang, Christine M. Tarby, Honghe Wan, Wayne Vaccaro, Guifen Zhang, Yufen Zhao, Kurt Zimmermann, Yong Zhang, Libing Chen, Bin Chen, John S. Tokarski, Ashvinikumar V. Gavai
  • IDO INHIBITORS
    Publication number: 20160060237
    Abstract: There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or autoimmune diseases utilizing the compounds of the invention. Formula (I).
    Type: Application
    Filed: March 12, 2014
    Publication date: March 3, 2016
    Inventors: James Aaron Balog, Audris Huang, Bin Chen, Libing Chen, Weifang Shan
  • Imidazotriazinecarbonitriles useful as kinase inhibitors
    Patent number: 9273057
    Abstract: The invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. The Formula (I) imidazotriazines inhibit protein kinase activity thereby making them useful as anticancer agents.
    Type: Grant
    Filed: July 12, 2013
    Date of Patent: March 1, 2016
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ashok Vinayak Purandare, Brian E. Fink, Walter Lewis Johnson, Amy C. Hart, Liqi He, Tram N. Huynh, Jennifer Inghrim, Harold Mastalerz, Xiaopeng Sang, Christine M. Tarby, Honghe Wan, Wayne Vaccaro, Guifen Zhang, Yufen Zhao, Kurt Zimmermann, Yong Zhang, Libing Chen, Bin Chen, John S. Tokarski, Ashvinikumar V. Gavai
  • INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE (IDO)
    Publication number: 20160022619
    Abstract: There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.
    Type: Application
    Filed: March 12, 2014
    Publication date: January 28, 2016
    Inventors: James Aaron Balog, Audris Huang, Bin Chen, Libing Chen, Steven P. Seitz, Amy C. Hart, Jay A. Markwalder
  • Medical trolley
    Patent number: D1059599
    Type: Grant
    Filed: November 1, 2023
    Date of Patent: January 28, 2025
    Inventors: Zhaopeng Chen, Tian Li, Fabian Wappler, Feng Li, Hanna Kim, Libing Dong, Hernan Herrero, Yukun Bai, Dongyang Bie